DK3036329T3 - Immunonkolytiske terapier - Google Patents

Immunonkolytiske terapier Download PDF

Info

Publication number
DK3036329T3
DK3036329T3 DK14837931.6T DK14837931T DK3036329T3 DK 3036329 T3 DK3036329 T3 DK 3036329T3 DK 14837931 T DK14837931 T DK 14837931T DK 3036329 T3 DK3036329 T3 DK 3036329T3
Authority
DK
Denmark
Prior art keywords
immunoncolytical
therapies
immunoncolytical therapies
Prior art date
Application number
DK14837931.6T
Other languages
English (en)
Inventor
Stephen Howard Thorne
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Application granted granted Critical
Publication of DK3036329T3 publication Critical patent/DK3036329T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK14837931.6T 2013-08-22 2014-08-22 Immunonkolytiske terapier DK3036329T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22
PCT/US2014/052308 WO2015027163A1 (en) 2013-08-22 2014-08-22 Immuno-oncolytic therapies

Publications (1)

Publication Number Publication Date
DK3036329T3 true DK3036329T3 (da) 2021-01-11

Family

ID=52484194

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14837931.6T DK3036329T3 (da) 2013-08-22 2014-08-22 Immunonkolytiske terapier
DK20189155.3T DK3778897T3 (da) 2013-08-22 2014-08-22 Immunonkolytiske terapier

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20189155.3T DK3778897T3 (da) 2013-08-22 2014-08-22 Immunonkolytiske terapier

Country Status (28)

Country Link
US (2) US11478518B2 (da)
EP (3) EP3036329B1 (da)
JP (3) JP6912199B2 (da)
KR (1) KR102389240B1 (da)
CN (1) CN105658795B (da)
AU (1) AU2014308648B2 (da)
CA (3) CA3213715A1 (da)
CY (1) CY1126587T1 (da)
DK (2) DK3036329T3 (da)
EA (1) EA037582B1 (da)
ES (2) ES2971528T3 (da)
FI (1) FI3778897T3 (da)
HR (1) HRP20240078T1 (da)
HU (1) HUE066593T2 (da)
IL (1) IL243996A0 (da)
LT (1) LT3778897T (da)
MD (2) MD4624C1 (da)
MX (1) MX2016002257A (da)
NZ (1) NZ716825A (da)
PE (1) PE20160673A1 (da)
PH (1) PH12016500329A1 (da)
PL (1) PL3778897T3 (da)
PT (1) PT3778897T (da)
RS (1) RS65104B1 (da)
SG (1) SG11201600960PA (da)
SI (1) SI3778897T1 (da)
SM (1) SMT202400047T1 (da)
WO (1) WO2015027163A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3036329T3 (da) * 2013-08-22 2021-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Immunonkolytiske terapier
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
WO2017014296A1 (ja) * 2015-07-22 2017-01-26 国立大学法人鳥取大学 ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子
HK1255192A1 (zh) * 2015-09-08 2019-08-09 Sillajen, Inc. 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
JP7025339B2 (ja) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
JP2019509326A (ja) * 2016-03-25 2019-04-04 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 合成エンベロープ化ウイルス
EP3254692A1 (en) * 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
JP7312695B2 (ja) * 2016-07-19 2023-07-21 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｓｔａｔ３を標的とする腫瘍溶解性ウイルス
CN110022867A (zh) * 2016-09-21 2019-07-16 斯蒂芬·H·索恩 高迁移率族蛋白box i突变体
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US12350303B2 (en) * 2017-02-03 2025-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic virus therapy
WO2018165161A1 (en) * 2017-03-06 2018-09-13 Novartis Ag Methods and compositions for determining the potency of a therapeutic cellular composition
KR20240132482A (ko) * 2017-04-21 2024-09-03 신라젠(주) 항암 백시니아 바이러스와 관문 저해제 병용 요법
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
CA3082961A1 (en) 2017-12-01 2019-06-06 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
MX2020007010A (es) * 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
EP3768698B1 (en) 2018-03-19 2025-02-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2020018996A2 (en) * 2018-07-20 2020-01-23 Ansun Biopharma, Inc. Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
CA3124287A1 (en) * 2018-12-21 2020-06-25 Ottawa Hospital Research Institute Modified orthopoxvirus vectors
CN113661236A (zh) * 2019-01-07 2021-11-16 卡利威尔免疫治疗公司 治疗癌症的方法
US11529402B2 (en) * 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP2022520220A (ja) * 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
JP7326663B2 (ja) * 2019-08-26 2023-08-16 バイオノックス インコーポレイテッド がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物
JP7625589B2 (ja) * 2019-10-16 2025-02-03 カリヴィル イムノセラピューティクス， インコーポレイテッド 改変細胞外エンベロープウイルス
WO2021102307A1 (en) * 2019-11-20 2021-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccinia viruses and methods for using vaccinia viruses
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CA3163805A1 (en) * 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
WO2021140435A1 (en) * 2020-01-09 2021-07-15 Pfizer Inc. Recombinant vaccinia virus
CN115243714A (zh) * 2020-03-06 2022-10-25 匹兹堡大学联邦系统高等教育 用于治疗癌症的表达irf调节剂的溶瘤病毒
JP2023532339A (ja) * 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
CA3197371A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
EP4329786A4 (en) * 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
US20240316104A1 (en) * 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
CA3260631A1 (en) * 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic and recombinant vaccine viruses and their methods of use
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
CA2375189C (en) 1999-05-28 2010-02-09 The Government Of The United States Of America A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
WO2007023725A1 (ja) * 2005-08-25 2007-03-01 Yokohama City University 遺伝子ワクチン
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2009124044A2 (en) * 2008-03-31 2009-10-08 University Of Florida Research Foundation, Inc. Tumor growth inhibition via conditioning of tumor microenvironment
BR112012005774B8 (pt) 2009-09-14 2023-02-14 Jennerex Inc uso de um inibidor de quinase antiangiogênico no tratamento de câncer
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
CN114262690A (zh) * 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
DK3036329T3 (da) 2013-08-22 2021-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Immunonkolytiske terapier

Also Published As

Publication number Publication date
DK3778897T3 (da) 2024-01-29
CA2921041A1 (en) 2015-02-26
EA201690444A1 (ru) 2016-08-31
CY1126587T1 (el) 2026-02-25
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
MD4624C1 (ro) 2019-10-31
CA3213683A1 (en) 2015-02-26
EP3036329B1 (en) 2020-10-07
SMT202400047T1 (it) 2024-03-13
JP2022062171A (ja) 2022-04-19
RS65104B1 (sr) 2024-02-29
EP3778897A1 (en) 2021-02-17
JP2016527920A (ja) 2016-09-15
IL243996A0 (en) 2016-04-21
MD4748B1 (ro) 2021-02-28
US11478518B2 (en) 2022-10-25
ES2971528T3 (es) 2024-06-05
EP4324918A2 (en) 2024-02-21
CN105658795B (zh) 2020-07-03
KR20160044529A (ko) 2016-04-25
HUE066593T2 (hu) 2024-08-28
FI3778897T3 (fi) 2024-01-25
AU2014308648B2 (en) 2020-11-12
US20230008089A1 (en) 2023-01-12
ES2847305T3 (es) 2021-08-02
MD4624B1 (ro) 2019-03-31
US20160235793A1 (en) 2016-08-18
CN105658795A (zh) 2016-06-08
HK1223402A1 (zh) 2017-07-28
CA3213715A1 (en) 2015-02-26
US12514888B2 (en) 2026-01-06
PH12016500329A1 (en) 2016-05-02
NZ716825A (en) 2022-02-25
WO2015027163A1 (en) 2015-02-26
SI3778897T1 (sl) 2024-03-29
EP3036329A4 (en) 2017-08-02
CA2921041C (en) 2023-10-31
MX2016002257A (es) 2016-11-08
JP2019205451A (ja) 2019-12-05
LT3778897T (lt) 2024-02-12
WO2015027163A9 (en) 2016-04-14
HRP20240078T1 (hr) 2024-03-29
JP7333431B2 (ja) 2023-08-24
SG11201600960PA (en) 2016-03-30
PT3778897T (pt) 2024-02-01
EP3036329A1 (en) 2016-06-29
EP4324918A3 (en) 2024-04-24
JP6912199B2 (ja) 2021-08-04
JP7021154B2 (ja) 2022-02-16
AU2014308648A1 (en) 2016-03-03
PE20160673A1 (es) 2016-07-21
KR102389240B1 (ko) 2022-04-20
MD4748C1 (ro) 2021-09-30
PL3778897T3 (pl) 2024-04-02
EA037582B1 (ru) 2021-04-16
EP3778897B1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
DK3778897T3 (da) Immunonkolytiske terapier
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
PT3055308T (pt) Resumo
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
DE112014005422A5 (de) Friktionsfalschdrallaggregat
BR112016000501A2 (pt) Nalador
ES1100380Y (es) Trompo
ES1093505Y (es) Aerociclo